Analyze RIGL

ShareShare on WhatsApp Share on Facebook Share on X

Equity Research · Deep diveIT-2026-RIGL · 2026-07-29

Rigel Pharmaceuticals, Inc. (RIGL)

HealthcareBiotechnologyNasdaqGSMarket cap $722.88M

$39.07

+1.48%

Analyst-style PDF, emailed within minutes

63/100

Positive bias

Automated weighted score · not a recommendation

Price source: Yahoo · live price · as of 23:00 · Data: Yahoo · SEC EDGAR · FINRA · Wikidata

About the company

Market cap

$722.88M

P/E

2.03

Beta

1.13

Employees

172

Sector: HealthcareIndustry: BiotechnologyExchange: NasdaqGSCountry: United States Website

What the company does

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Day range

$37.95$39.94

52-week range

$19.51$52.24

Price alert on RIGL

Get an in-app and mobile alert every time RIGL crosses a price you set.

Loading short data…

RIGL · Chart

Loading chart…

SMA20 SMA50 SMA200

Charts by TradingView

Support & resistance

Key trading levels, by timeframe

Day

Swing

Computing levels…

The technical signal compass

Sign up free and build your own trading bot with full backtesting. Live bots, real-time alerts and the bot gallery — with a Pro subscription.

Free sign-up

Rigel Pharmaceuticals, Inc. (RIGL) is trading around $39.07 (+1.48% on the last session). Its 52-week range runs from $19.51 to $52.24. Technically: 5 buy signals, 2 sell and 5 neutral. It belongs to the Healthcare sector (Biotechnology), with a P/E of 2.0 and a 723M$ market cap. Data sourced from Yahoo · live price as of 23:00. This is data analysis only, not advice or a recommendation.

RIGL stock FAQ

What is RIGL's current price?

RIGL is trading around $39.07 (+1.48%), as of 23:00 per Yahoo · live price.

What is RIGL's 52-week price range?

Over the last 52 weeks RIGL ranged between a $19.51 low and a $52.24 high.

Which sector does RIGL belong to?

RIGL belongs to the Healthcare sector, Biotechnology industry.

Disclosure & disclaimer: All information, scores, signals and trade plans on this site are produced by an automated algorithmic system and are based on technical and quantitative data only. They do not constitute investment advice, investment marketing or a recommendation to act, and are not a substitute for personal advice from a licensed professional that accounts for your needs and circumstances. We are not investment advisors. Trading securities involves substantial risk, up to the loss of your entire investment; every decision and action is your sole responsibility. i-trade and its operators bear no liability for any direct or indirect damage arising from reliance on this information.

0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼# € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1買 0 0 買 ↑ % 0 ▼ ₿ $ $ ₿ ▼ 0 % ↑ 買 0 0 買 ↑ %€ ↓ ↓ € ▲ 売 # 1 1 ◇ ◇ 1 1 # 売 ▲ € ↓ ↓ € ▲ 売0 ▼ ▼ 0 0 ₿ 買 % $ ↑ ↑ $ % 買 ₿ 0 0 ▼ ▼ 0 0 ₿↓ 1 1 ↓ # 1 € 売 ◇ ▲ ▲ ◇ 売 € 1 # ↓ 1 1 ↓ # 1▼ % % ▼ 買 $ 0 ₿ ↑ 0 0 ↑ ₿ 0 $ 買 ▼ % % ▼ 買 $1 売売 1 € ◇ ↓ 1 ▲ # # ▲ 1 ↓ ◇ € 1 売売 1 € ◇% ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲₿ $ $ ₿ ▼ 0 % ↑ 買 0 0 買 ↑ % 0 ▼ ₿ $ $ ₿ ▼ 01 ◇ ◇ 1 1 # 売 ▲ € ↓ ↓ € ▲ 売 # 1 1 ◇ ◇ 1 1 #$ ↑ ↑ $ % 買 ₿ 0 0 ▼ ▼ 0 0 ₿ 買 % $ ↑ ↑ $ % 買◇ ▲ ▲ ◇ 売 € 1 # ↓ 1 1 ↓ # 1 € 売 ◇ ▲ ▲ ◇ 売 €↑ 0 0 ↑ ₿ 0 $ 買 ▼ % % ▼ 買 $ 0 ₿ ↑ 0 0 ↑ ₿ 0▲ # # ▲ 1 ↓ ◇ € 1 売売 1 € ◇ ↓ 1 ▲ # # ▲ 1 ↓0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼# € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1

Building the strategy

RIGL stock FAQ

What is RIGL's current price?

RIGL is trading around $39.07 (+1.48%), as of 23:00 per Yahoo · live price.

What is RIGL's 52-week price range?

Over the last 52 weeks RIGL ranged between a $19.51 low and a $52.24 high.

Which sector does RIGL belong to?

RIGL belongs to the Healthcare sector, Biotechnology industry.

Analyze RIGL

Rigel Pharmaceuticals, Inc. (RIGL)

About the company

RIGL · Chart

Support & resistance

The technical signal compass

RIGL stock FAQ

Rigel Pharmaceuticals, Inc. (RIGL)

About the company

RIGL · Chart

Support & resistance

The technical signal compass

RIGL stock FAQ

Income statement analysis

Institutional & insider data

Full analyst coverage